Who is sponsoring NCT06138496?

NCT06138496 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06138496?

Interventions in NCT06138496: Cadonilimab Combined With Lenvatinib.

What condition does NCT06138496 study?

NCT06138496 studies Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy.

Is NCT06138496 still recruiting?

NCT06138496 is currently completed. Last updated 5 January 2026.

Last reviewed 2026-01-05 · How we verify

NCT06138496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Completed Phase 2 Last updated 5 January 2026

What this trial tests

Phase 2 trial testing Cadonilimab Combined With Lenvatinib in Cadonilimab in 39 participants. Completed in 31 December 2025.

Timeline

1 September 2023

Primary endpoint
9 December 2024

31 December 2025

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	1 September 2023
Primary completion	9 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Cadonilimab Combined With Lenvatinib — full drug profile →

Conditions studied

Cadonilimab — all drugs for Cadonilimab →
Clear Cell Renal Cell Carcinoma — all drugs for Clear Cell Renal Cell Carcinoma →
Neoadjuvant Therapy — all drugs for Neoadjuvant Therapy →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 80, any sex, with Cadonilimab or Clear Cell Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through the neoadjuvant treatment with a combination of Cardonilli and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Renal cancer: signaling pathways and advances in targeted therapies.
Jiang A, Li J, He Z, Liu Y, et al · · 2024 · cited 18× · PMID 39092291 · DOI 10.1002/mco2.676
Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies.
Khorasanchi A, Jatwani K, Meng L, Collier KA, et al · · 2024 · PMID 39766027 · DOI 10.3390/cancers16244127

Verify or expand the search:

Other recruiting trials for Cadonilimab

Currently open trials in the same condition.

NCT06367088 — Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Brea · Phase 2 · recruiting
NCT06405490 — NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC · Phase 2 · recruiting
NCT06265350 — Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases · NA · recruiting
NCT06218810 — Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06138496 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 5 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06138496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing